PE20160787A1 - Nuevo compuesto para el tratamiento de hipoglicemia severa - Google Patents

Nuevo compuesto para el tratamiento de hipoglicemia severa

Info

Publication number
PE20160787A1
PE20160787A1 PE2016000823A PE2016000823A PE20160787A1 PE 20160787 A1 PE20160787 A1 PE 20160787A1 PE 2016000823 A PE2016000823 A PE 2016000823A PE 2016000823 A PE2016000823 A PE 2016000823A PE 20160787 A1 PE20160787 A1 PE 20160787A1
Authority
PE
Peru
Prior art keywords
treatment
new compound
severe hypoglycemia
glu
leu
Prior art date
Application number
PE2016000823A
Other languages
English (en)
Inventor
Robert Chadwick Cummins
Jorge Alsina-Fernandez
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52278803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160787(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20160787A1 publication Critical patent/PE20160787A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Removal Of Specific Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Referida a un compuesto de glucagon caracterizado porque comprende la secuencia de amioacidos de Tyr-Ser-His-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Lys-Tyr-Leu-Asp-(Aib)-Lys-Lys-Ala-Ala-Glu-Phe-Val-Ala-Trp-Leu-Leu-Glu-Glu (SEQ ID N°: 2). Dicho compuesto es util en el tratamiento de la hipoglicemia.
PE2016000823A 2013-12-18 2014-12-11 Nuevo compuesto para el tratamiento de hipoglicemia severa PE20160787A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361917658P 2013-12-18 2013-12-18

Publications (1)

Publication Number Publication Date
PE20160787A1 true PE20160787A1 (es) 2016-08-17

Family

ID=52278803

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000823A PE20160787A1 (es) 2013-12-18 2014-12-11 Nuevo compuesto para el tratamiento de hipoglicemia severa

Country Status (26)

Country Link
US (1) US9688736B2 (es)
EP (1) EP3083669A1 (es)
JP (1) JP2017503782A (es)
KR (1) KR20160077215A (es)
CN (1) CN105793282A (es)
AP (1) AP2016009268A0 (es)
AR (1) AR098616A1 (es)
AU (1) AU2014366427B2 (es)
BR (1) BR112016012505A2 (es)
CA (1) CA2928987A1 (es)
CL (1) CL2016001473A1 (es)
CR (1) CR20160223A (es)
DO (1) DOP2016000128A (es)
EA (1) EA201691036A1 (es)
EC (1) ECSP16024805A (es)
HK (1) HK1224303A1 (es)
IL (1) IL245399A0 (es)
MA (1) MA39108A1 (es)
MX (1) MX2016007984A (es)
NZ (1) NZ719451A (es)
PE (1) PE20160787A1 (es)
PH (1) PH12016501184A1 (es)
SG (1) SG11201604232TA (es)
TN (1) TN2016000180A1 (es)
TW (1) TW201609129A (es)
WO (1) WO2015094878A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2019140024A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
CA3128922A1 (en) 2019-02-05 2020-08-13 Eli Lilly And Company Glucagon analog agonists and methods of using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG177953A1 (en) * 2007-01-05 2012-02-28 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
CA2713348C (en) 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
AU2009260302B2 (en) 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CN102088989B (zh) 2008-06-17 2014-11-26 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
MX342409B (es) 2010-01-20 2016-09-28 Zealand Pharma As Tratamiento de enfermedades cardiacas.
CA2788304A1 (en) 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
US20130053310A1 (en) * 2010-03-26 2013-02-28 Novo Nordisk A/S Novel glucagon analogues
CA2792663A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
MX2012014576A (es) 2010-06-24 2013-02-21 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida.
EP2585482B1 (en) 2010-06-24 2019-03-27 Zealand Pharma A/S Glucagon analogues
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
AU2011348202A1 (en) 2010-12-22 2013-07-04 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides
EP2665487A1 (en) 2011-01-20 2013-11-27 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
CN103596583B (zh) * 2011-03-28 2016-07-27 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물

Also Published As

Publication number Publication date
AP2016009268A0 (en) 2016-06-30
ECSP16024805A (es) 2017-02-24
WO2015094878A1 (en) 2015-06-25
CR20160223A (es) 2016-07-12
DOP2016000128A (es) 2016-06-30
AU2014366427A1 (en) 2016-05-19
BR112016012505A2 (pt) 2017-09-26
AU2014366427B2 (en) 2017-02-16
PH12016501184A1 (en) 2016-07-25
SG11201604232TA (en) 2016-07-28
NZ719451A (en) 2017-10-27
CN105793282A (zh) 2016-07-20
TN2016000180A1 (en) 2017-10-06
KR20160077215A (ko) 2016-07-01
TW201609129A (zh) 2016-03-16
US9688736B2 (en) 2017-06-27
EA201691036A1 (ru) 2016-12-30
AR098616A1 (es) 2016-06-01
IL245399A0 (en) 2016-06-30
JP2017503782A (ja) 2017-02-02
HK1224303A1 (zh) 2017-08-18
MA39108A1 (fr) 2017-11-30
EP3083669A1 (en) 2016-10-26
MX2016007984A (es) 2016-09-09
US20160311883A1 (en) 2016-10-27
CA2928987A1 (en) 2015-06-25
CL2016001473A1 (es) 2017-03-10

Similar Documents

Publication Publication Date Title
CY1121114T1 (el) Αγωνιστες γλυκαγονης/glp-1 για τη θεραπεια της παχυσαρκιας
PE20150900A1 (es) Derivados de exendida-4 como agonistas duales de glp1/glucagon
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
EA201370178A1 (ru) Стабильные составы для парентеральной инъекции пептидных лекарственных средств
CL2016001405A1 (es) A peptide mixture
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
UA118558C2 (uk) Пептидна сполука
NZ717035A (en) Cortistatin analogues for the treatment of inflammatory and/or immune diseases
PE20160787A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
CR20160227A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
GT201600117A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
CY1119212T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
TH168459A (th) สารประกอบใหม่สำหรับการรักษาภาวะน้ำตาลในเลือดต่ำอย่างรุนเเรง
NZ733839A (en) Amino acid and peptide conjugates and conjugation process
EA201791103A1 (ru) Терапевтический гомодимер и его применения
TH168629B (th) สารประกอบใหม่สำหรับการรักษาภาวะน้ำตาลในเลือดต่ำอย่างรุนแรง
TH168459B (th) สารประกอบใหม่สำหรับการรักษาภาวะน้ำตาลในเลือดต่ำอย่างรุนเเรง

Legal Events

Date Code Title Description
FD Application declared void or lapsed